User profiles for "author:Anique Ducharme"

Anique Ducharme

Université de Montreal
Verified email at UMONTREAL.CA
Cited by 16056

CCS/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction

M McDonald, S Virani, M Chan, A Ducharme… - Canadian Journal of …, 2021 - Elsevier
In this update of the Canadian Cardiovascular Society heart failure (HF) guidelines, we
provide comprehensive recommendations and practical tips for the pharmacologic …

The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure

RS McKelvie, GW Moe, JA Ezekowitz… - Canadian Journal of …, 2013 - Elsevier
Abstract The 2012 Canadian Cardiovascular Society Heart Failure (HF) Guidelines Update
provides management recommendations for acute and chronic HF. In 2006, the Canadian …

Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or …

JMO Arnold, JG Howlett, P Dorian, A Ducharme… - Canadian Journal of …, 2007 - Elsevier
Heart failure is common, yet it is difficult to treat. It presents in many different guises and
circumstances in which therapy needs to be individualized. The Canadian Cardiovascular …

[HTML][HTML] Rhythm control versus rate control for atrial fibrillation and heart failure

D Roy, M Talajic, S Nattel, DG Wyse… - … England Journal of …, 2008 - Mass Medical Soc
Background It is common practice to restore and maintain sinus rhythm in patients with atrial
fibrillation and heart failure. This approach is based in part on data indicating that atrial …

[HTML][HTML] Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction

A Ducharme, S Frantz, M Aikawa… - The Journal of …, 2000 - Am Soc Clin Investig
Matrix metalloproteinase-9 (MMP-9) is prominently overexpressed after myocardial
infarction (MI). We tested the hypothesis that mice with targeted deletion of MMP9 have less …

Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials

E Vermes, JC Tardif, MG Bourassa, N Racine… - Circulation, 2003 - Am Heart Assoc
Background—Atrial fibrillation (AF) is frequently encountered in patients with heart failure
(HF) and is also a predictor of morbidity and mortality in this population. Recent …

2017 Comprehensive update of the Canadian Cardiovascular Society guidelines for the management of heart failure

JA Ezekowitz, E O'Meara, MA McDonald… - Canadian Journal of …, 2017 - Elsevier
Since the inception of the Canadian Cardiovascular Society heart failure (HF) guidelines in
2006, much has changed in the care for patients with HF. Over the past decade, the HF …

Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial

JA Lindenfeld, MR Zile, AS Desai, K Bhatt, A Ducharme… - The Lancet, 2021 - thelancet.com
Background Previous studies have suggested that haemodynamic-guided management
using an implantable pulmonary artery pressure monitor reduces heart failure …

[HTML][HTML] Cystatin C deficiency in human atherosclerosis and aortic aneurysms

GP Shi, GK Sukhova, A Grubb… - The Journal of …, 1999 - Am Soc Clin Investig
The pathogenesis of atherosclerosis and abdominal aortic aneurysm involves breakdown of
the elastic laminae. Elastolytic cysteine proteases, including cathepsins S and K, are …

Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure …

LG Olsson, K Swedberg, A Ducharme… - Journal of the American …, 2006 - jacc.org
Objectives: We assessed the risk of adverse cardiovascular (CV) outcomes associated with
atrial fibrillation (AF) in the Candesartan in Heart failure-Assessment of Reduction in …